Drugs / mRNA-1010.4
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05868382 | May → Dec 2023 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1010.4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05868382 ↗ |
| Route | Intramuscular | “Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.” NCT05868382 ↗ |